+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 15Years - 39Years
FEMALE
Healthy Volunteers
ID06743204

Integrated Sexually Transmitted Infection Testing and Risk Screening to Improve Pre-Exposure Prophylaxis Use Among African Women

Led by Johns Hopkins University · Updated on 2026-09-18

5560

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the impact of integrating female curable sexually transmitted infection cSTI testing with self-reported risk screening tools SRST to improve pre-exposure prophylaxis PrEP use among cis-gender African women aged 15 to 39 years. The study aims to address the challenge that many women at high risk for HIV are not identified by current screening methods and that PrEP use often declines shortly after initiation. This research is nested within the Rakai Community Cohort Study in Uganda, focusing on HIV prevention and control in a high-burden region. Participants will be randomly assigned to one of two groups one receiving standard self-reported risk screening plus diagnostic testing for chlamydia, gonorrhea, trichomonas, and syphilis, and the other receiving self-reported risk screening alone. Both groups will have access to syndromic case management for STIs and syphilis testing for pregnant women. Women who test positive for cSTIs or meet PrEP eligibility based on screening will be referred for same-day PrEP initiation and provided free treatment for themselves and their partners if diagnosed with an STI. During the study, participants will be evaluated for PrEP uptake, adherence, and persistence up to six months after enrollment through surveys, clinical records, and drug level testing. Additional qualitative interviews will explore factors influencing PrEP use and cSTI testing implementation. Mathematical modeling will assess optimal cSTI testing strategies for reducing HIV incidence and improving population health. The total study duration extends through 2029, with primary outcomes measured up to six months after enrollment.

CONDITIONS

Brief Title

The Integrated Female Sexually Transmitted Infection Testing for HIV Epidemic Control Through PrEP (IN-STEP) Study

Research Team

M

Mary Kathryn Grabowski, Associate Professor, PhD

R

Ronald M Galiwango, Ugandan PI, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here